Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 19/06/2015, Revision: 24, Status: Authorised

Case Medical Research ◽

10.31525/cmr-39973f ◽

2019 ◽

Author(s):

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Small Cell ◽

Hodgkin Disease ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 19/06/2015, Revision: 27, Status: Authorised

Case Medical Research ◽

10.31525/cmr-962c37 ◽

2019 ◽

Author(s):

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Small Cell ◽

Hodgkin Disease ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Carcinoma, Non-Small-Cell Lung,Breast Neoplasms,Ovarian Neoplasms,Colorectal Neoplasms,Carcinoma, Renal Cell, Date of authorisation: 12/01/2005, Revision: 51, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1b3e44e ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Colorectal Neoplasms ◽

Renal Cell ◽

Ovarian Neoplasms ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Carcinoma, Renal Cell,Peritoneal Neoplasms,Ovarian Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Fallopian Tube Neoplasms, Date of authorisation: 14/01/2018, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-4e9a82 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

Peritoneal Neoplasms ◽

European Public ◽

European Public Assessment Report ◽

Fallopian Tube Neoplasms ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Carcinoma, Renal Cell,Peritoneal Neoplasms,Ovarian Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Fallopian Tube Neoplasms, Date of authorisation: 14/01/2018, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-58719b ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

Peritoneal Neoplasms ◽

European Public ◽

European Public Assessment Report ◽

Fallopian Tube Neoplasms ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 17, Status: Authorised

Case Medical Research ◽

10.31525/cmr-ad8c98 ◽

2019 ◽

Author(s):

Keyword(s):

Small Cell ◽

Hodgkin Disease ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 21, Status: Authorised

Case Medical Research ◽

10.31525/cmr-ac5652 ◽

2019 ◽

Author(s):

Keyword(s):

Small Cell ◽

Hodgkin Disease ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Carcinoma, Transitional Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 20/09/2017, Revision: 5, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1569c6a ◽

2019 ◽

Author(s):

Keyword(s):

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Transitional Cell ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Colorectal Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Carcinoma, Renal Cell,Uterine Cervical Neoplasms, Date of authorisation: 14/02/2019, Revision: 1, Status: Authorised

Case Medical Research ◽

10.31525/cmr-12a1fc3 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

Cervical Neoplasms ◽

Cell Lung Carcinoma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Breast Neoplasms,Pancreatic Neoplasms,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 10/01/2008, Revision: 24, Status: Authorised

Case Medical Research ◽

10.31525/cmr-15997e6 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Pancreatic Neoplasms ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Carcinoma, Non-Small-Cell Lung,Mesothelioma, Date of authorisation: 18/01/2016, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1b3e451 ◽

2019 ◽

Author(s):

Keyword(s):

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text